+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

From
Recurrent Or Metastatic Head And Neck Cancer Market - Product Thumbnail Image

Recurrent Or Metastatic Head And Neck Cancer Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Neuroendocrine Tumors Market - Product Thumbnail Image

Neuroendocrine Tumors Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Gastric Neuroendocrine Tumors Market - Product Thumbnail Image

Gastric Neuroendocrine Tumors Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Cancer Immunotherapy Market - Forecasts from 2025 to 2030 - Product Thumbnail Image

Cancer Immunotherapy Market - Forecasts from 2025 to 2030

  • Report
  • August 2025
  • 144 Pages
  • Global
From
From
From
From
From
From
Immuno-Oncology Clinical Trials Market Report 2023-2033 - Product Thumbnail Image

Immuno-Oncology Clinical Trials Market Report 2023-2033

  • Report
  • September 2023
  • 249 Pages
  • Global
From
CCR8-Targeted Antibody Immunotherapy Pipeline Review - Product Thumbnail Image

CCR8-Targeted Antibody Immunotherapy Pipeline Review

  • Report
  • September 2025
  • Global
From
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more